Clinical Trial Update: Gene Therapy for Fanconi Anemia, Complementation Group A [Phase 2]

View source ↗

Summary

This entry reports a Phase 2 gene therapy trial for Fanconi anemia, complementation group A, which is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fanconi Anemia

Drugs mentioned

• Rocket Pharma FANCA gene therapy (investigational) (FANCA gene therapy)

Snippet

Sponsor: Rocket Pharmaceuticals Inc. | Conditions: Fanconi Anemia Complementation Group A | Phase 2 | Status: ACTIVE_NOT_RECRUITING